Eli Lilly and Company (NYSE:LLY) Shares Sold by Advanced Asset Management Advisors Inc

Advanced Asset Management Advisors Inc cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 42.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 401 shares of the company’s stock after selling 294 shares during the period. Advanced Asset Management Advisors Inc’s holdings in Eli Lilly and Company were worth $234,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Van Cleef Asset Management Inc increased its holdings in Eli Lilly and Company by 18.5% in the 4th quarter. Van Cleef Asset Management Inc now owns 3,676 shares of the company’s stock valued at $2,143,000 after purchasing an additional 575 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich grew its stake in shares of Eli Lilly and Company by 12.2% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 555,002 shares of the company’s stock valued at $323,522,000 after buying an additional 60,538 shares in the last quarter. Abbrea Capital LLC grew its stake in shares of Eli Lilly and Company by 4.2% in the fourth quarter. Abbrea Capital LLC now owns 9,426 shares of the company’s stock valued at $5,495,000 after buying an additional 383 shares in the last quarter. Syon Capital LLC raised its holdings in shares of Eli Lilly and Company by 13.4% in the 4th quarter. Syon Capital LLC now owns 10,788 shares of the company’s stock valued at $6,289,000 after buying an additional 1,274 shares during the period. Finally, Meritage Portfolio Management lifted its stake in Eli Lilly and Company by 23.4% during the 4th quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock worth $3,717,000 after acquiring an additional 1,208 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LLY. Morgan Stanley lifted their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. BMO Capital Markets lifted their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Finally, Barclays upped their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $728.05.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Performance

NYSE:LLY traded down $7.33 during trading hours on Thursday, reaching $724.87. 2,597,583 shares of the company’s stock were exchanged, compared to its average volume of 3,034,002. Eli Lilly and Company has a 1-year low of $370.68 and a 1-year high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a market capitalization of $688.74 billion, a price-to-earnings ratio of 124.61, a P/E/G ratio of 1.63 and a beta of 0.34. The company has a 50-day moving average of $763.40 and a 200 day moving average of $664.52.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the prior year, the company earned $2.09 earnings per share. The business’s revenue was up 28.1% compared to the same quarter last year. Research analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.